Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory designation

FDA grants RPD designation to Quoin's QRX003 for PSS

Analysis based on 10 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026

Sentiment
40
Attention
2
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The RPD designation enhances Quoin's regulatory and commercial prospects for QRX003, potentially adding significant non-dilutive value through PRVs. This positive regulatory milestone is likely to support Quoin's stock price and investor sentiment in the near term.

Biotechnology Pharmaceuticals

On September 8, 2026, the U.S. United States — Food and Drug Administration granted Rare Pediatric Disease (RPD) Designation to Quoin Pharmaceuticals' lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). This is the second RPD designation for QRX003, following a prior designation for Netherton Syndrome. The designation makes Quoin eligible to receive a Priority Review Voucher (PRV) upon approval of a New Drug Application for QRX003 for PSS, potentially yielding two PRVs with an aggregate non-dilutive cash value exceeding $300 million based on current trading values. Quoin expects to initiate a Phase 2 clinical study in the second half of 2026, enrolling up to 12 pediatric and adult PSS patients in the U.S. and Europe. There are currently no approved treatments for PSS, a rare autosomal recessive skin disorder caused by CDSN gene variants.

stock
Quoin is the developer of QRX003 and the recipient of the RPD designation, which strengthens its pipeline and potential for PRV-derived value.
Importance 100.0 Sentiment 70.0
govactor
The FDA granted the RPD designation, a regulatory action that provides incentives for developing treatments for rare pediatric diseases.
Importance 80.0 Sentiment 0.0
per
Michael Myers is the CEO of Quoin Pharmaceuticals and is quoted in the announcement, representing the company's leadership.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.